左乙拉西坦治疗典型学龄期儿童良性癫痫伴中央颞区棘波的临床观察

Clinical Observation of Levetiracetam Treatment of Classic School-Age Children with Benign Epilepsy with Centro-Temporal Spikes

目的观察左乙拉西坦（LEV）治疗学龄期（7～14岁）儿童的典型良性癫痫伴中央颞区棘波（BECT）的疗效和安全性，并分析其临床价值。方法采用前瞻性研究，对64例典型BECT患儿给予LEV治疗，分析单药治疗后1、2、4、6、12、18个月的疗效和不良反应。LEv起始剂量为10mg／（kg·d），每隔7d增加1次剂量10mg／（kg·d），维持剂量20—60mg／（kg·d）。结果本组总有效率为90．63％，服药18个月时累积控制率为78．13％，留存率为98．44％，均呈现较高比率。结论LEV治疗典型BECT的疗效明显，不良反应轻，安全性高，值得临床推广应用。

Objective To observe the clinical efficacy and safety of levetiracetam （LEV） in treating classic benign epilepsy with centro-temporal spikes （BECT） at school-age （7 - 14 years old） children, and to analyze its clinical value. Methods With the method of prospectively studied, 64 children with BECT received LEV therapy to analyze the efficacy and adverse reactions after the LEV monotherapy 1, 2, 4, 6, 12 and 18 months. The starting dose of LEV was l0 mg/（kgod）; increased 10 mg/（kg-d） every seven days; and titrated up to 20-60 mg/（kg.d）. Result The total effective rate was 90.63%; the cumulative control rate after 18-month medication was 78.13%; and the retention rate was 98.44%. Those all showed a higher rate. Conclusion LEV is significantly effective to BECT with less adverse reactions and more safety. It is worthy of clinical application.